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Abstract
On the basis of the reported association between hepatitis B vaccination (HBvacc) and autoimmune demyelinating
complications such as multiple sclerosis (MS), we have looked for aminoacid similarities between the small hepatitis B virus
surface antigen (SHBsAg), and the MS-autoantigens myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein
(MOG) that could serve as targets of immunological cross-reactivity. Twenty-mer peptides spanning 4 SHBsAg/MOG and 1
SHBsAg/MBP mimicking pairs, were constructed and tested by ELISA as targets of cross-reactive responses. A total of 147
samples from 58 adults were collected before HBvacc (58/58), and post-HBvacc (48/58 before the second and 41/58 before
the third boost). Eighty-seven sera from anti-SHBsAg antibody negative patients with various diseases were tested as
pathological controls. Reactivity to at least one of the SHBsAg peptides was found in 8 (14%) pre-HBvacc subjects; amongst
the remaining 50, reactivity to at least one of the SHBsAg peptides appeared in 47 (94%) post-HBvacc. Reactivity to at least
one of the MOG mimics was present in 4 (8%) pre-HBvacc and in 30 (60%) post-HBvacc (p , 0.001). Overall 30/50 (60%)
vaccinees had SHBsAg/MOG double reactivity on at least one occasion compared to none before-vaccination and in 2 (2%) of
the pathological controls (p , 0.001 for both). SHBsAg/MOG double reactivity was cross-reactive as conﬁrmed by inhibition
studies. At 6 months post-vaccination, 3 of the4 anti-MOG reactivecases before vaccination and 7 of the 24 (29%) of the anti-
MOG reactive cases at 3 months post-vaccination had lost their reactivity to MOG5-24. There was no reactivity to the
SHBsAg/MBP mimics. None of the vaccinees reported symptoms of demyelinating disorders. In view of the observed
SHBsAg/MOG cross-reactivity, the vaccine’s possible role as an immunomodulator of viral/self cross-reactivity must be
further investigated.
Keywords: Autoantibody, autoimmunity, hepatitis B virus, multiple sclerosis, vaccination
Abbreviations: EAE, experimental autoimmune encephalomyelitis; SHBsAg, small hepatitis B surface antigen; MBP,
myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; OD, optical density; SI, stimulation
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Introduction
Molecular mimicry based on amino acid similarities
shared by viral and self antigens has long been
proposed as a pathogenic mechanism for autoimmune
disease but documentation of this mechanism has
been elusive in humans because infection probably
occurs years before the clinically overt autoimmune
disease (Dyrberg and Oldstone 1986; 1989; 1998;
Bogdanos et al. 2000; Van de Water et al. 2001).
Presently, proof for molecular mimicry relies on the
availability of viral mimics able to induce cross-
reactive immune responses leading to tissue damage in
experimental animals such as experimental auto-
immune encephalomyelitis (EAE), the animal model
of multiple sclerosis and herpes stromal keratitis
(Oldstone 1998; Wucherpfennig 2001; von Herrath
et al. 2003).
The information derived from animal studies is of
undoubted value but experimental models of human
disease are not always able to reproduce faithfully
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cal cross-reactivity in serum samples before and after
vaccination against viruses may provide useful
information as to how a viral stimulus can induce
cross-reactive autoimmune responses. Indeed, it has
been proposed that vaccination against infectious
agents may activate pathways of molecular mimicry in
genetically susceptible hosts, and this may be the basis
of adverse reactions to vaccines (Cohen and Shoenfeld
1996; Poirriez 2004; Ravel et al. 2004). In the present
study we have used vaccination against hepatitis B
virus (HBVacc) as a model for the study of viral/self
cross-reactivity.
The current HBVacc is a non-infectious viral
subunit consisting of the small hepatitis B virus
surface antigen (SHBsAg), a 226 aa long recombinant
antigen identical to the “wild” SHBsAg (Shouval
2003). Extrahepatic autoimmune manifestations,
such as demyelinating disorders and MS have
increasingly been linked to HBVacc administration
suggesting that the exposure to SHBsAg may be
capable of inducing autoimmune adverse reactions
(Herroelen et al. 1991; Cohen and Shoenfeld 1996;
Maillefert et al. 1999; Shoenfeld and Aron-Maor
2000; Aron-Maor and Shoenfeld 2001; Vital et al.
2002; Poirriez 2004; Ravel et al. 2004). The fact that
the HBVacc is administered in three doses over a
period of seven months gives the opportunity to study
the emergence of the humoral antiviral immune
response and, at the same time, to witness appearance
and evolution of the possible cross-reactive auto-
immunity as a consequence of exposure to SHBsAg.
Among various myelin antigens, myelin basic
protein (MBP) is the major target of MS and EAE
(Raine and Bornstein 1970; Martin et al. 1992;
Steinman 1996). More recent studies indicate that
humoral immunity against myelin oligodendrocyte
glycoprotein (MOG) is associated with myelin
damage in MS (Devaux et al. 1997; Genain et al.
1999; Wekerle 1999). Having found through screen-
ing of protein databases that known epitopic regions
on SHBsAg share extensive homologies with MBP
and MOG, we have investigated whether the viral/self
mimics serve as target of cross-reactive immune
responses following HBVacc administration in healthy
individuals.
Material and methods
Subjects
A total of 234 serum samples stored in the Institute of
Liver Studies, King’s College Hospital, London, were
tested including 147 samples pre- and post-HB
vaccination from 58 adults (median age 42, range
31–62, 38 male), negative for hepatitis B viral
markers. Samples were collected before HBvacc
(58/58), and post-HBvacc, at three months (48/58)
before the second boost, and six months post-HBvacc
(41/58) before the third boost. As pathological
controls, 87 anti-HBsAg antibody negative patients
(median age 45, range 22–74, 59 female) were tested
including 23 with primary biliary cirrhosis (PBC), 27
with alcoholic liver disease (ALD), 19 with auto-
immune thyroiditis, and 18 with systemic lupus
erythematosus (SLE).
All sera were tested under code. Informed consent
was obtained from each subject. The project was
approved by the local ethical committee.
Anti-viral antibody detection
A commercially available ELISA (Research Diagnos-
tics, Flanders, NJ, USA) was used to detect IgG
antibodies against SHBsAg.
Protein database search and analysis
The “BLASTp 2 sequences” programme (available at
http://www.ncbi.nlm.nih.gov/ BLAST) was used to
search for amino acid sequence similarity between
SHBsAg and the MBP and MOG myelin antigens.
Peptide synthesis
To assess cross-reactivity between SHBsAg and
homologous self-sequences (Figure 1), seven 20-
mer peptidyl mimics were constructed (Mimotopes
Ltd, Clayton, Australia) as reported in Table I.
An irrelevant, randomly generated 20-mer peptide
(-HEDYVNQSLRPTPLEISVRA-) served as control
(Bogdanos et al. 2002, 2004a; b, 2005; Kerkar et al.
2003). Peptides conformed to the following format:
Biotin- SGSG-peptide-amide, in which SGSG is a
spacer with alternating serine (S) and glycine (G)
residues to avoid steric hindrance and reduce
hydrophobicity. Biotin-captured peptides allow maxi-
mum absorbance at minimal antigen concentration,
therefore providing a signiﬁcant advantage over
uncaptured peptides relying on random binding on
plates, which at times requires high antigen concen-
trations and results in high background noise
(Bogdanos et al. 2002; 2004a; b; 2005; Kerkar et al.
2003). Peptide purity was $90% as determined by
analytical reverse phase high-performance liquid
chromatography. The identity of each puriﬁed peptide
was conﬁrmed by mass spectrometry. On arrival, 1mg
of each freeze-dried peptide was dissolved in 40%
acetonitrile (Sigma-Aldrich Biochemical, Dorset,
UK), aliquoted, and stored at 2708C.
Anti-peptide antibody detection
Antibody binding to the peptides was determined by
ELISA, as described previously (Bogdanos et al. 2002;
2004a; b; 2005; Kerkar et al. 2003). Brieﬂy, 100mlo f
D.-P. Bogdanos et al. 218peptide diluted in phosphate buffer saline (PBS,
Sigma-Aldrich) containing 0.1% bovine serum albu-
min (BSA, Sigma-Aldrich) and 0.1% sodium azide
(ﬁnal peptide concentration, 5mg/ml) was added to
96-well streptavidin coated microplates (Mimotopes).
The optimal concentrations of reagents at various
steps of the immunoassay were determined in
preliminary experiments by checkerboard titration.
After 90-minute incubation and washing, plates were
incubated with 100ml/well of serum diluted in 2%
BSA/PBS containing 0.1% sodium azide (ﬁnal
dilution, 1/100). Plates were washed, and 100ml/well
of horseradish peroxidase- conjugated rabbit anti-total
human immunoglobulin (Dako Ltd, High Wycombe,
Bucks, UK), diluted 1/4000 in 2% BSA/PBS, was
added. The reaction was developed by the addition of
100ml/well ofo-phenylenediamine solution containing
0.4mg/ml of 3% hydrogen peroxide in citrate
phosphate buffer (Sigma-Aldrich) and terminated
with 100ml/well of 4N H2SO4. Absorbance (optical
density, OD) was read in a microplate reader (MRX;
Dynex Technologies, West Sussex, UK) at 490nm.
Each serum tested against experimental peptides was
also tested against the control peptide. The ﬁnal
Figure 1. Amino acid sequence homology between small Hepatitis B surface antigen (SHBsAg) and myelin antigens. Amino acids in
standard single letter; Full stop (.), conservative substitution. MOG, myelin oligodendrocyte glycoprotein; MBP, myelin basic protein.
Table I. Single and double reactivity to SHBsAg and myelin mimics in absolute numbers and percentages (%), in 50 vaccinees before and
after vaccination.
Pre-HBVacc baseline n=50 Post-HBVacc 3 months n=45 Post-HBVacc 6 months n=39
SHBsAg130-149 0/50 (0%) 41/45(91%) 37/39 (95%)
SHBsAg80-99 0/50 (0%) 1/45 (2%) 0/39 (0%)
SHBsAg1-20 0/50 (0%) 10/45 (22%) 13/39 (33%)
SHBsAg65-84 0/50 (0%) 5/45 (11%) 5/39 13(%)
SHBsAg (at least 1peptide) 0/50 (0%) 42/45 (93%) 37/39 (39%)
MOG5-24 4/50 (8%) 24/45 (53%) 14/39 (36%)
MOG210-229 1/50 (2%) 8/45 (17%) 5/39 (13%)
MOG (at least 1peptide) 4/50 (8%) 24/45 (53%) 16/39 (41%)
MBP80-99 0/50 (0%) 0/45 (0%) 0/39 (0%)
SHBsAg130-149/MOG5-24 0/50 (0%) 23/45 (51%) 16/39 (41%)
SHBsAg80-99/MOG5-24 0/50 (0%) 1/45 (2%) 0/39 (0%)
SHBsAg1-20/MOG210-229 0/50 (0%) 7/45 (16%) 5/39 (13%)
SHBsAg (full protein) 0/50 (0%) 40/45 (89%) 36/39 (92%)
SHBsAg/MOG (at least 1pair) 0/50 (0%) 21/45 (47%) 16/39 (41%)
HBVacc, hepatitis B vaccination; SHBsAg, small hepatitis B surface antigen; MOG, myelin oligodendrocyte glycoprotein; MBP, myelin basic
protein.
Mimicry and vaccination 219absorbance value was calculated as the absorbance
(OD)
test peptide/OD
control peptide. Reaction to a given
peptide was considered positive when OD
test/OD
con-
trol peptide was $2; this cut off representing mean þ 5
SD of 135 readings using serum (tested in triplicate)
from 15 healthy subjects against the mimicking
peptides. Expression of absorbance as ratios of
OD
test/OD
control peptide avoids false-positive results
caused by nonspeciﬁc binding to unrelated peptides in
hypergammaglobulinemic serum samples (Bogdanos
et al. 2002; 2004a; b; 2005; Kerkar et al. 2003). All
experiments were done in triplicate.
Inhibition studies
To investigate whether the simultaneous reactivity to
SHBsAg130-149 and MOG5-24 was due to cross-
reactivity, competition ELISA were performed as
previously described (Bogdanos et al. 2002; 2004a;
b; 2005; Kerkar et al. 2003), measuring residual anti-
SHBsAg130-14 antibody reactivity after incubation
respectively with SHBsAg130-14, MOG5-24, recombi-
nant SHBsAg antigen (Research Diagnostics), the
irrelevant control peptide and control protein (cyto-
chrome P450IID6, Pharmacia, Milton Keynes, UK)
as liquid phase competitors. Antibody detection was
carried out under identical conditions to those
described in ELISA.
Statistical analysis
Results are presented as mean ^ SD or as percentages
(%). Data were analysed using t-test, Mann-Whitney
U-test, chi-square (x
2) test and the Fisher’s exact test
as appropriate. Correlations between variables were
assessed using the Spearman rank order correlation
coefﬁcient. A two-tailed p value less than 0.05 was
considered signiﬁcant. Statistical analyses were per-
formed using SPSS (SPSS Inc., Chicago, IL, USA)
statistical package.
Results
Protein database search and analysis
Amino acid similarities between SHBsAg (226 aa) and
the MPB (304 aa) and MOG (247 aa) antigens are
illustrated in Figure 1. Overlapping sequences within
MOG10-22 share a 66–86% local homology with
SHBsAg135-140 and SHBsAg83-98. Another pair of
viral/self mimics involves SHBsAg9-15 and MOG218-
224 (100% homology). SHBsAg135-140 is part of the
immunodominant “a” B-cell epitope on SHBsAg;
SHBsAg83-98 is part of the leucine zipper pattern of
SHBsAg and MOG10-22 extensively overlaps with the
encephalitogenic epitope MOG1-20 (Landschulz et al.
1988; Genain et al. 1999).
The best homology between SHBsAg and MBP is
that of the SHBsAg67-80/MBP82-95 pair (8/14 homo-
logy) (Figure 1).
ELISA
Before vaccination
Reactivity to at least one of the SHBsAg peptides was
found in 8 (14%) pre-vaccinated subjects (including 3
cases with antibodies to the full-length SHBsAg) who
were excluded from the study.
Amongst the remaining 50 cases, reactivity to at
least one of the MOG peptides was present in 4 (8%)
(Table I).
At 3 months post-vaccination
Reactivity to at least one of the SHBsAg peptides was
present in 41/45 (91%) of the vaccinated subjects
(Table I), all of whom reacted with SHBsAg130-149
(Table II). Antibodies against the full-length SHBsAg
were present in 40/45 (89%) of the cases.
Reactivity to at least one of the MOG mimics was
present in 24/45 (53%) of the cases, all but one
reacting with MOG5-24 (Table I and II).
Double reactivity to at least one SHBsAg/MOG
mimicking pairs was present in 24/45 (53%) of the
cases (Table I and II).
At 6 months post-vaccination
Reactivity to at least one of the SHBsAg peptides was
present in 36/39 (92%) of the cases (Table I), all of
who reacted with SHBsAg130-149. All 36 cases also had
antibodies against the full-length SHBsAg.
Overall, 47/50 (94%) of the post vaccinated cases
had anti-SHBsAg antibody protective immunity
(median anti-SHBsAg antibody titre: 386mIU/ml,
range 16–1000mIU/ml, cut off ¼ 10mIU/ml).
Reactivity to at least one of the MOG mimics was
present in 17/39 (44%) of the cases. At 6 months post-
vaccination, 3 of the 4 anti-MOG reactive cases before
vaccination and 7 of the 24 (29%) of the anti-MOG
reactive cases at 3 months post-vaccination had lost
their reactivity to MOG5-24.
Double reactivity to at least one SHBsAg/MOG
mimicking pairs was present in 16/39 (41%) of the
cases.
Overall 30/50 (60%) vaccinees had SHBsAg/MOG
double reactivity on at least one occasion (either at 3
or 6 months post-vaccination) compared to none
before-vaccination (p , 0.001) and in 2/87 (2%,
p , 0.001) of the pathological controls (a 52-year old
woman with PBC and a 28-year old woman with
SLE). None of the vaccinees or the pathological
controls had double reactivity to the SHBsAg/MBP
mimicking pair.
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Mimicry and vaccination 221None of the vaccinees reported symptoms of
demyelinating disorders at the 6-month post-vacci-
nation follow-up.
Inhibition studies
Antibody binding to SHBsAg130-149 was inhibited by
73–92% after pre-incubation with the SHBsAg130-
149; by 69–85% after pre-incubation with MOG5-24
and by 74–88% after pre-incubation with full-length
SHBsAg, in all 3 cases tested (Figure 2). Insigniﬁcant
inhibition was observed by pre-incubation with the
irrelevant control peptide and antigen (Figure 2).
Discussion
In the present study we have looked for evidence of
cross-reactivity between SHBsAg and myelin mimics
in normal subjects undergoing hepatitis B vaccination.
Not only does SHBsAg share strong homologies with
major myelin antigens such as MBP and MOG but
also speciﬁc viral/self pairs were found to be targets of
antibody responses induced by the administration of
the viral vaccine. As for other previously described
mimics (Quaratino et al. 1995; Bogdanos et al. 2004a,
b, 2005), sequence similarity per se did not necessarily
lead to anti-peptide reactivity and immunological
cross-reactivity (Oldstone 1987). In the present study
the SHBsAg/MBP mimicking sequences and two of
four sets of SHBsAg/MOG mimics were not antibody
targets (Table I). Inhibition studies have demonstrated
the cross-reactive nature of the observed SHBsAg/-
MOG antibody responses (Figure 2). The selective
appearance of viral/myelin cross-reactive responses in
some but not all of the mimicking pairs supports the
biological signiﬁcance of the present ﬁndings (Old-
stone, 1987, 1989, 1998).
The question of a connection between vaccination
and autoimmune disorders is surrounded by con-
troversy (Herroelen et al. 1991; Cohen and Shoenfeld
1996; Maillefert et al. 1999; Shoenfeld and Aron-
Maor, 2000; Aron-Maor and Shoenfeld, 2001; Vital
et al. 2002; Poirriez 2004; Ravel et al. 2004; Girard
2005; Selmi et al. 2005). A heated debate is going on
regarding the causality between anti-HBV vaccination
and demyelinating disorders such as multiple sclerosis
(Cohen and Shoenfeld 1996; Marshall 1998; Aron-
Maor and Shoenfeld 2001; Ascherio et al. 2001;
Confavreux et al. 2001; Geier and Geier 2001; Girard
2005; Selmi et al. 2005). The focus of the present
study was the application of HBV vaccination as a
model for the study of immunological cross-reactivity
rather than the study of the safety and efﬁcacy of the
anti-HBV vaccination. Serum samples from HBV
vaccination recipients with established autoimmune
disorders have not been tested in the present study. All
of the vaccinees were free of autoimmune phenomena
before vaccination and remain free of any adverse
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D.-P. Bogdanos et al. 222reactions during the follow up. Clues as to the
pathogenic link between the vaccine and speciﬁc
autoimmune disorders, therefore, could not be
established. Cross-reactive immunity was found only
after vaccination, though decreasing in magnitude
over time with a signiﬁcant proportion of vaccinated
subjects maintaining the anti-viral response but losing
that against self. These ﬁndings suggest that upon
vaccination, induction of an anti-viral response is
initially capable of promoting cross-reactive anti-self
immune responses, which decrease over time, possibly
as a result of peripheral tolerance mechanisms. This
scenario may explain why very rarely adverse post-
vaccination autoimmune reactions occur (Ascherio
et al. 2001; Confavreux et al. 2001). Equally
important may be the ﬁnding that the minority of
vaccinees with an anti-myelin reactivity pre-HBV
vaccination almost universally lost this reactivity post-
vaccination. It is possible to speculate that the viral
components of the vaccine and in particular the self
mimicking SHBsAg sequences may play a role as
altered peptide ligand, i.e. may represent sequences
unable to induce cross-reactive responses but able to
promote tolerance to a given autoepitope (Sloan-
Lancaster and Allen 1996). Such mechanism could
probably be of beneﬁt in patients with multiple
sclerosis in whom HBV vaccination or immunomo-
dulatory treatment with SHBsAg mimics as altered
peptide ligand might contribute to restoration of
tolerance towards myeling antigens (Sloan-Lancaster
and Allen 1996).
The hepatitis B vaccine is the ﬁrst vaccine which has
been shown to prevent cancer, and it has saved—and
will save—millions of lives (Shouval 2003). But is also
a vaccine against a virus which has been pathogeneti-
cally linked to autoimmune adverse reactions
(Herroelen et al. 1991; Cohen and Shoenfeld 1996;
Maillefert et al. 1999; Shoenfeld and Aron-Maor
2000; Aron-Maor and Shoenfeld 2001; Vital et al.
2002; Poirriez 2004; Ravel et al. 2004). In view of the
observed SHBsAg/MOG cross-reactivity, the vac-
cine’s possible role as a trigger for the induction and/or
maintenance of viral/self cross-reactivity through
molecular mimicry must be further investigated.
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